Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.
about
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.'Who', 'when' and 'how' in re-irradiation of recurrent painful bone metastases.Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.
P2860
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Docetaxel rechallenge after a ...... vity with manageable toxicity.
@en
Docetaxel rechallenge after a ...... vity with manageable toxicity.
@nl
type
label
Docetaxel rechallenge after a ...... vity with manageable toxicity.
@en
Docetaxel rechallenge after a ...... vity with manageable toxicity.
@nl
prefLabel
Docetaxel rechallenge after a ...... vity with manageable toxicity.
@en
Docetaxel rechallenge after a ...... vity with manageable toxicity.
@nl
P2093
P2860
P1476
Docetaxel rechallenge after a ...... vity with manageable toxicity.
@en
P2093
C Donamaria
G MacGrogan
H Bonnefoi
M Toulmonde
N Madranges
P2860
P2888
P304
P356
10.1007/S10549-012-2060-2
P407
P577
2012-04-25T00:00:00Z